Luminal - A型乳腺癌的化疗(5)

breast cancer: evidence from a phrase III randomized trail [J].J Clin Oncol, 2001, 19(18):3808.

[10] Carey LA, Dees EC, Sawye L, et al.The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes [J]. Clin Cancer Res, 2007, 13: 2329 - 2334.

[11] Sofia B, Lissandra dL, Chantal B, et al. Use of trastuzumab for the treatment of early stage breast cancer [J]. Expet Rev Anticancer Ther, 2006, 6(8):1153-1164.

[12] Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma [J]. Clin Cancer Res, 2004, 10(16):5367-74.

[13] Dent R, Trudeau M, Pritchard KI, et al. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence [J]. Clin Cancer Res, 2007, 13: 4429-4434.

[14] El Weshi A, Tulbah A, Al Sayed A, et al. Triple negative breast cancer. A clinicopathological study of 113 cases and comparison with 55 cases with triple positive breast cancer: A match control analysis. J

Clin Oncol, 2007(ASCO Annual Meeting), 25(18S, Part I): A21119.

[15] Finak G, Sadekova S, Pepin F, et al. Gene expression signatures of morphologically normal breast tissue identify basal-like tumors [J].Breast Cancer Res. 2006; 8(5):R58.

[16] Early Breast Cancer Trialists’ Collaborative Group

(EBCTCG).

Adjuvant

polychemotherapy

in

oestrogen-receptor-poor breast cancer: meta-analysis of individual patient data from the randomised trials The Lancet 2008; 371: 29-40.

[17] Harold J.Burstein, Soonmyung Paik, Peter M, et al. Ajuvant Chemotherapy for Patients with Estrogen Receptor-Positive Breast Cancer.ASCO 2006 Educational Book: 49-55.

[18] Henri Roché, Pierre Fumoleau, Marc Spielmann, et al. Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006; 24:5664-5671.

[19] Colleoni M, Li S, Gelber RD, et al.Timing of CMF chemotherapy in combination with tamoxifen in

postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol. 2005; 16(5): 716-25.

[20] Judith Hugh, John Hanson, Maggie Chon U. et al. Breast Cancer Subtypes and Response to Docetaxel in Node-Positive

Breast

Cancer:

Use

of

an

Immunohistochemical Definition in the BCIRG 001 Trial. J Clin Oncol 2009: 27:1168-1176.

[21] Hayes DF, Thor AD, Dressler LG, et al: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496-1506.

[22] Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658-1667.

[23] Goldstein, L. J., O'Neill, A., Sparano, J. A., et al. Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197. JCO 2008; 26: 4092-4099. [24] Y. Ohashi, T. Watanabe, M. Sano, et al. Efficacy

of oral tegafur-uracil (UFT) as adjuvant therapy as compared

with

classical

cyclophosphamide,

methotrexate, and 5-fluorouracil (CMF) in early breast cancer: A pooled analysis of two randomized controlled trials (N-SAS-BC01 trial and CUBC trial). J Clin Oncol 27:15s, 2009 (suppl; abstr 578).

[25] P. Martin, C. Mazouni, F. André, et al. Impact of the mode of estrogen receptor determination on breast cancer prognosis. J Clin Oncol 27, 2009 (suppl; abstr e11609).

[26] Michele De Laurentiis, Giuseppe Cancello, Diego D'Agostino, et al. Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials Journal of Clinical Oncology, Vol 26, No 1 (January 1), 2008: pp. 44-53. [27] Fabrice Andre, Kristine Broglio, Henri Roche, et al. Estrogen Receptor Expression and Efficacy of Docetaxel Containing Adjuvant Chemotherapy in Patients with Node-Positive Breast Cancer: Results from a Pooled Analysis. J Clin Oncol 2008；26:2636-2643.

[28] Frédérique Penault-Llorca, Fabrice André, Christine Sagan, et al. Ki67 Expression and Docetaxel

Efficacy in Patients with Estrogen Receptor–Positive Breast Cancer. Journal of Clinical Oncology, Vol 27, No 17 (June 10), 2009: pp. 2809-2815.

[29] Lyndsay Harris.Herbert Fritsche, Robert Mennel, et al. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol 2007；25:5287-5312. [30] M.

Cheang,

S.

K.

Chia,

D.

Tu,

et

al.Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. J Clin Oncol 27:15s, 2009 (suppl; abstr 519).

[31] M. J. Piccart-Gebhart.Who benefits from taxanes? 2009 ASCO Annual Meeting Abstract No: e11503. [32] van 't Veer LJ, Dai H, van de Vijver MJ, et al.. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002；415 (6871): 530-6. [33] F. A. de Snoo, M. Knauer, R. A. Bender, et al. Outcome prediction by the 70-gene profile in the context of the National Comprehensive Cancer Network (NCCN) guidelines. J Clin Oncol 27:15s, 2009 (suppl; abstr 535).

[34] R. A. Bender, M. Knauer, E. J. Rutgers, et al.

百度搜索“77cn”或“免费范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读，免费范文网，提供经典小说综合文库Luminal - A型乳腺癌的化疗(5)在线全文阅读。